Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Large Decrease in Short Interest

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 16,697 shares, a drop of 17.9% from the December 15th total of 20,342 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 3,946 shares, the short-interest ratio is currently 4.2 days. Based on an average daily trading volume, of 3,946 shares, the short-interest ratio is currently 4.2 days. Currently, 0.0% of the shares of the company are short sold.

Molecular Partners Stock Performance

MOLN opened at $4.17 on Monday. The stock’s 50 day moving average price is $4.26 and its 200-day moving average price is $3.92. Molecular Partners has a one year low of $3.36 and a one year high of $5.55. The stock has a market cap of $168.42 million, a price-to-earnings ratio of -2.17 and a beta of 1.07.

Molecular Partners (NASDAQ:MOLN) last issued its earnings results on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05. As a group, analysts predict that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on MOLN. JPMorgan Chase & Co. decreased their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.88.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.